Fortress Biotech, Inc.
FBIOP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001429260
In the last 90 days, Fortress Biotech, Inc. insiders filed 2 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q3 2026; no superinvestor holds it.
Other share classesFBIO
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysLast 90 days, $340.4K in total
- 2
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026
- 0
- 13F valueReported value at the end of Q3 2026
- $0
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $63.3M
- +9.7% year over year
- Net income, FY2025
- $6.82M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- $19.2M
- +8.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net income for FY2025: $6.82M (10.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 455
- Shares sold short
- Change
- +455
- +100.0% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding FBIOP, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding FBIOP at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Fortress Biotech, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 19, 2026 (view filing)5:59 PM ET | Nov 17-19 | 2 days | Rosenwald Lindsay A MDPRESIDENT, CEO & CHAIRMAN | PPurchaseCommon Stock, par value $0.001 | +136.7K | $1.85 | +$252.6K | +3.0%4.72M after | 3 lots |
| Nov 19, 2026 (view filing)5:54 PM ET | Nov 17-19 | 2 days | Jin DavidChief Financial Officer | PPurchaseCommon Stock, par value $0.001 | +47.6K | $1.84 | +$87.8K | +2.9%1.70M after | 3 lots |
| Sep 25, 2024 (view filing)4:45 PM ET | Sep 23 | 2 days | Rosenwald Lindsay A MDPRESIDENT, CEO & CHAIRMAN | PPurchaseCommon stock, par value $0.001 | +763.4K | $1.84 | +$1.40M | +26.4%3.66M after | |
| Sep 25, 2024 (view filing)4:45 PM ET | Sep 23 | 2 days | Rosenwald Lindsay A MDPRESIDENT, CEO & CHAIRMAN | PPurchase | +763.4K | $0.125 | +$95.4K | –763.4K after | Derivative |
| Jul 15, 2024 (view filing) | Jul 11 | 4 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +5.00K | $7.48 | +$37.4K | +4.1%127.5K after | |
| Jul 12, 2024 (view filing) | Jul 10 | 2 days | Jin DavidChief Financial Officer | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +500 | $7.50 | +$3.75K | New position500 after | |
| Jul 11, 2024 (view filing) | Jul 9 | 2 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +5.00K | $7.39 | +$37.0K | +4.3%122.5K after | |
| Jul 10, 2024 (view filing) | Jul 8 | 2 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +5.00K | $7.35 | +$36.8K | +4.4%117.5K after | |
| Jul 1, 2024 (view filing) | Jun 28 | 3 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseCOMMON STOCK, PAR VALUE $0.001 | +20.0K | $1.64 | +$32.8K | +0.7%2.89M after | |
| May 20, 2024 (view filing) | May 16 | 4 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseCOMMON STOCK, PAR VALUE $0.001 | +10.0K | $1.76 | +$17.6K | +0.3%2.87M after |
Top 10 13F holders, Q3 2026
View all: Top 10 13F holders, Q3 2026The largest institutional positions in Fortress Biotech, Inc. at the end of Q3 2026; share changes are against Q2 2026.
No institution reported holding FBIOP in 13F filings for Q3 2026.